The Renin-Angiotensin-Aldosterone System in Podocytes

Seminars in Nephrology

Volumn 32, Issue 4, 2012, Pages 377-384

  Wennmann, Dirk Oliver ^a   Hsu, Hsiang Hao ^a,b   Pavenstädt, Hermann ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

Aldosterone; Angiotensin II; Podocyte; Prorenin receptor

Indexed keywords

ALDOSTERONE; ALISKIREN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ANGIOTENSINOGEN; APOCYNIN; CALCIUM ION; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPLERENONE; HYDRALAZINE; LISINOPRIL; MINERALOCORTICOID RECEPTOR; PLACEBO; PRORENIN RECEPTOR; RENIN INHIBITOR; ROSIGLITAZONE; ROTENONE; SPIRONOLACTONE; TEMPOL; TRANSIENT RECEPTOR POTENTIAL CHANNEL 6;

ALBUMINURIA; APOPTOSIS; ARTICLE; AUTOPHAGY; CALCIUM CELL LEVEL; CALCIUM SIGNALING; CHRONIC KIDNEY DISEASE; DIABETIC NEPHROPATHY; ENDOPLASMIC RETICULUM STRESS; ENDOTHELIUM CELL; FOCAL GLOMERULOSCLEROSIS; GENE EXPRESSION; GLOMERULUS FILTRATION; HUMAN; HYPERTENSION; KIDNEY FAILURE; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ALDOSTERONE; ANGIOTENSIN II; ANIMALS; HUMANS; PODOCYTES; RECEPTORS, ANGIOTENSIN; RECEPTORS, CELL SURFACE; RENIN-ANGIOTENSIN SYSTEM; SIGNAL TRANSDUCTION;

EID: 84865799862     PISSN: 02709295     EISSN: 15584488     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2012.06.009     Document Type: Article

References (62)

1. Hemmelgarn B.R., Manns B.J., Lloyd A., et al. Relation between kidney function, proteinuria, and adverse outcomes. JAMA 2010, 303:423-429.
2. Krause M.W., Fonseca V.A., Shah S.V. Combination inhibition of the renin-angiotensin system: is more better?. Kidney Int 2011, 80:245-255.
3. Nitschke R., Henger A., Ricken S., et al. Angiotensin II increases the intracellular calcium activity in podocytes of the intact glomerulus. Kidney Int 2000, 57:41-49.
4. Gloy J., Henger A., Fischer K.G., et al. Angiotensin II depolarizes podocytes in the intact glomerulus of the Rat. J Clin Invest 1997, 99:2772-2781.
5. Seikaly M.G., Arant B.S., Seney F.D. Enhanced angiotensin concentrations in specific intrarenal fluid compartments of the rat. J Clin Invest 1990, 86:1352-1357.
6. Hoffmann S., Podlich D., Hähnel B., Kriz W., Gretz N. Angiotensin II type 1 receptor overexpression in podocytes induces glomerulosclerosis in transgenic rats. J Am Soc Nephrol 2004, 15:1475-1487.
7. Lapinski R., Perico N., Remuzzi A., et al. Angiotensin II modulates glomerular capillary permselectivity in rat isolated perfused kidney. J Am Soc Nephrol 1996, 7:653-660.
8. Huby A.C., Rastaldi M.P., Caron K., et al. Restoration of podocyte structure and improvement of chronic renal disease in transgenic mice overexpressing renin. PLoS One 2009, 4:e6721.
9. Winn M.P., Conlon P.J., Lynn K.L., et al. A mutation in the TRPC6 cation channel causes familial focal segmental glomerulosclerosis. Science 2005, 308:1801-1804.
10. Eckel J., Lavin P.J., Finch E.A., et al. TRPC6 enhances angiotensin II-induced albuminuria. J Am Soc Nephrol 2011, 22:526-535.
11. Nijenhuis T., Sloan A.J., Hoenderop J.G., et al. Angiotensin II contributes to podocyte injury by increasing TRPC6 expression via an NFAT-mediated positive feedback signaling pathway. Am J Pathol 2011, 179:1719-1732.
12. Matsusaka T., Asano T., Niimura F., et al. Angiotensin receptor blocker protection against podocyte-induced sclerosis is podocyte angiotensin II type 1 receptor-independent. Hypertension 2010, 55:967-973.
13. Hsu H.H., Hoffmann S., Di Marco G., et al. Down-regulation of peroxiredoxin 2 contributes to angiotensin II-mediated podocyte apoptosis. Kidney Int 2011, 80:959-969.
14. Inagami T. Molecular biology and signaling of angiotensin receptors: an overview. J Am Soc Nephrol 1999, 10(Suppl 1):S2-S7.
15. Bouby N., Hus-Citharel A., Marchetti J., et al. Expression of type 1 angiotensin II receptor subtypes and angiotensin II-induced calcium mobilization along the rat nephron. J Am Soc Nephrol 1997, 8:1658-1667.
16. Crowley S.D., Vasievich M.P., Ruiz P., et al. Glomerular type 1 angiotensin receptors augment kidney injury and inflammation in murine autoimmune nephritis. J Clin Invest 2009, 119:943-953.
17. Harrison-Bernard L.M., Monjure C.J., Bivona B.J. Efferent arterioles exclusively express the subtype 1A angiotensin receptor: functional insights from genetic mouse models. Am J Physiol Renal Physiol 2006, 290:F1177-F1186.
18. Rüster C., Bondeva T., Franke S., et al. Angiotensin II upregulates RAGE expression on podocytes: role of AT2 receptors. Am J Nephrol 2009, 29:538-550.
19. Liebau M.C., Lang D., Böhm J., et al. Functional expression of the renin-angiotensin system in human podocytes. Am J Physiol Renal Physiol 2006, 290:F710-F719.
20. Yoo T.H., Li J.J., Kim J.J., et al. Activation of the renin-angiotensin system within podocytes in diabetes. Kidney Int 2007, 71:1019-1027.
21. Xu Z.G., Miao L.N., Cui Y.C., et al. Angiotensin II type 1 receptor expression is increased via 12-lipoxygenase in high glucose-stimulated glomerular cells and type 2 diabetic glomeruli. Nephrol Dial Transplant 2009, 24:1744-1752.
22. Durvasula R.V., Petermann A.T., Hiromura K., et al. Activation of a local tissue angiotensin system in podocytes by mechanical strain. Kidney Int 2004, 65:30-39.
23. Durvasula R.V., Shankland S.J. Activation of a local renin angiotensin system in podocytes by glucose. Am J Physiol Renal Physiol 2008, 294:F830-F839.
24. Sakoda M., Ichihara A., Kurauchi-Mito A., et al. Aliskiren inhibits intracellular angiotensin II levels without affecting (pro)renin receptor signals in human podocytes. Am J Hypertens 2010, 23:575-580.
25. Phillips L.M., Wang Y., Dai T., et al. The renin inhibitor aliskiren attenuates high-glucose induced extracellular matrix synthesis and prevents apoptosis in cultured podocytes. Nephron Exp Nephrol 2011, 118:e49-e59.
26. Wang L., Flannery P.J., Spurney R.F. Characterization of angiotensin II-receptor subtypes in podocytes. J Lab Clin Med 2003, 142:313-321.
27. Velez J.C., Bland A.M., Arthur J.M., Raymond J.R., Janech M.G. Characterization of renin-angiotensin system enzyme activities in cultured mouse podocytes. Am J Physiol Renal Physiol 2007, 293:F398-F407.
28. Giani J.F., Muñoz M.C., Pons R.A., et al. Angiotensin-(1-7) reduces proteinuria and diminishes structural damage in renal tissue of stroke-prone spontaneously hypertensive rats. Am J Physiol Renal Physiol 2011, 300:F272-F282.
29. Mentzel S., van Son J.P., Dijkman H.B., Wetzels J.F., Assmann K.J. Induction of albuminuria in mice: synergistic effect of two monoclonal antibodies directed to different domains of aminopeptidase A. Kidney Int 1999, 55:1335-1347.
30. Cousin C., Bracquart D., Contrepas A., Nguyen G. Potential role of the (pro)renin receptor in cardiovascular and kidney diseases. J Nephrol 2010, 23:508-513.
31. Nguyen G., Delarue F., Burckle C., et al. The renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 2002, 109:1417-1427.
32. Cruciat C.M., Ohkawara B., Acebron S.P., et al. Requirement of prorenin receptor and vacuolar H+-ATPase-mediated acidification for Wnt signaling. Science 2010, 327:459-463.
33. Matavelli L.C., Huang J., Siragy H.M. (Pro)renin receptor contributes to diabetic nephropathy by enhancing renal inflammation. Clin Exp Pharmacol Physiol 2010, 37:277-282.
34. Ichihara A., Hayashi M., Kaneshiro Y., et al. Inhibition of diabetic nephropathy by a decoy peptide corresponding to the "handle" region for nonproteolytic activation of prorenin. J Clin Invest 2004, 114:1128-1135.
35. Nguyen G., Muller D.N. The biology of the (pro)renin receptor. J Am Soc Nephrol 2010, 21:18-23.
36. Riediger F., Quack I., Qadri F., et al. Prorenin receptor is essential for podocyte autophagy and survival. J Am Soc Nephrol 2011, 22:2193-2202.
37. Chrysostomou A., Becker G. Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. N Engl J Med 2001, 345:925-926.
38. Ando K., Ohtsu H., Arakawa Y., et al. Rationale and design of the Eplerenone combination Versus conventional Agents to Lower blood pressure on Urinary Antialbuminuric Treatment Effect (EVALUATE) trial: a double-blinded randomized placebo-controlled trial to evaluate the antialbuminuric effects of an aldosterone blocker in hypertensive patients with albuminuria. Hypertens Res 2010, 33:616-621.
39. Shibata S., Nagase M., Yoshida S., Kawachi H., Fujita T. Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1. Hypertension 2007, 49:355-364.
40. Nagase M., Shibata S., Yoshida S., et al. Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker. Hypertension 2006, 47:1084-1093.
41. Zhu C., Huang S., Yuan Y., et al. Mitochondrial dysfunction mediates aldosterone-induced podocyte damage: a therapeutic target of PPARã. Am J Pathol 2011, 178:2020-2031.
42. Shibata S., Nagase M., Yoshida S., et al. Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease. Nat Med 2008, 14:1370-1376.
43. Shankland S.J. The podocyte's response to injury: role in proteinuria and glomerulosclerosis. Kidney Int 2006, 69:2131-2147.
44. Ding G., Reddy K., Kapasi A.A., et al. Angiotensin II induces apoptosis in rat glomerular epithelial cells. Am J Physiol Renal Physiol 2002, 283:F173-F180.
45. Wang L., Chang J.H., Paik S.Y., et al. Calcineurin (CN) activation promotes apoptosis of glomerular podocytes both in vitro and in vivo. Mol Endocrinol 2011, 25:1376-1386.
46. Vassiliadis J., Bracken C., Matthews D., et al. Calcium mediates glomerular filtration through calcineurin and mTORC2/Akt signaling. J Am Soc Nephrol 2011, 22:1453-1461.
47. Chen Y., Klionsky D.J. The regulation of autophagy-unanswered questions. J Cell Sci 2011, 124:161-170.
48. Hartleben B., Gödel M., Meyer-Schwesinger C., et al. Autophagy influences glomerular disease susceptibility and maintains podocyte homeostasis in aging mice. J Clin Invest 2010, 120:1084-1096.
49. Yadav A., Vallabu S., Arora S., et al. ANG II promotes autophagy in podocytes. Am J Physiol Cell Physiol 2010, 299:C488-C496.
50. Saleem M.A., Zavadil J., Bailly M., et al. The molecular and functional phenotype of glomerular podocytes reveals key features of contractile smooth muscle cells. Am J Physiol Renal Physiol 2008, 295:F959-F970.
51. Eekhoff A., Bonakdar N., Alonso J.L., Hoffmann B., Goldmann W.H. Glomerular podocytes: a study of mechanical properties and mechano-chemical signaling. Biochem Biophys Res Commun 2011, 406:229-233.
52. Hsu H.H., Hoffmann S., Endlich N., et al. Mechanisms of angiotensin II signaling on cytoskeleton of podocytes. J Mol Med 2008, 86:1379-1394.
53. Jia J., Ding G., Zhu J., et al. Angiotensin II infusion induces nephrin expression changes and podocyte apoptosis. Am J Nephrol 2008, 28:500-507.
54. Miceli I., Burt D., Tarabra E., et al. Stretch reduces nephrin expression via an angiotensin II-AT(1)-dependent mechanism in human podocytes: effect of rosiglitazone. Am J Physiol Renal Physiol 2010, 298:F381-F390.
55. Suzuki K., Han G.D., Miyauchi N., et al. Angiotensin II type 1 and type 2 receptors play opposite roles in regulating the barrier function of kidney glomerular capillary wall. Am J Pathol 2007, 170:1841-1853.
56. Benigni A., Tomasoni S., Gagliardini E., et al. Blocking angiotensin II synthesis/activity preserves glomerular nephrin in rats with severe nephrosis. J Am Soc Nephrol 2001, 12:941-948.
57. Macconi D., Abbate M., Morigi M., et al. Permselective dysfunction of podocyte-podocyte contact upon angiotensin II unravels the molecular target for renoprotective intervention. Am J Pathol 2006, 168:1073-1085.
58. Hayashi K., Sasamura H., Ishiguro K., et al. Regression of glomerulosclerosis in response to transient treatment with angiotensin II blockers is attenuated by blockade of matrix metalloproteinase-2. Kidney Int 2010, 78:69-78.
59. van den Hoven M.J., Waanders F., Rops A.L., et al. Regulation of glomerular heparanase expression by aldosterone, angiotensin II and reactive oxygen species. Nephrol Dial Transplant 2009, 24:2637-2645.
60. Chen S., Lee J.S., Iglesias-de la Cruz M.C., et al. Angiotensin II stimulates alpha3(IV) collagen production in mouse podocytes via TGF-beta and VEGF signalling: implications for diabetic glomerulopathy. Nephrol Dial Transplant 2005, 20:1320-1328.
61. Brinkkoetter P.T., Holtgrefe S., van der Woude F.J., Yard B.A. Angiotensin II type 1-receptor mediated changes in heparan sulfate proteoglycans in human SV40 transformed podocytes. J Am Soc Nephrol 2004, 15:33-40.
62. Liang X.B., Ma L.J., Naito T., et al. Angiotensin type 1 receptor blocker restores podocyte potential to promote glomerular endothelial cell growth. J Am Soc Nephrol 2006, 17:1886-1895.